RNA therapeutics are drugs whose active substance is nucleic acid — small interfering RNA, antisense oligonucleotides, or messenger RNA — acting on the instructions a cell reads rather than blocking a finished protein. The category earned its standing one approval at a time: FDA approved Qfitlia (fitusiran), the first siRNA drug for hemophilia A or B, on March 28, 2025.
What are the main RNA modalities, mechanically?
Three mechanisms carry the field. Small interfering RNA recruits the cell's own RNA-induced silencing complex to degrade a target messenger RNA, reducing production of the encoded protein; fitusiran lowers antithrombin, a protein that inhibits clot formation, in people with hemophilia A or B. Antisense oligonucleotides bind a target RNA to block it, splice it, or modulate it. Messenger RNA delivers instructions for a cell to express a protein transiently, the mechanism behind the authorized COVID-19 vaccines. The shared engineering problem is delivery: naked RNA degrades quickly, so conjugation chemistry — GalNAc conjugation for liver targets in siRNA drugs, lipid nanoparticles for mRNA — decides where the drug goes before its sequence decides what it does.
What did the fitusiran approval actually establish?
FDA approved Qfitlia on March 28, 2025 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors, per the FDA press announcement. The sponsor called it the sixth U.S. approval of an Alnylam-discovered RNAi therapeutic, and the first and only therapeutic to lower antithrombin, per Alnylam's March 28, 2025 release — a company-claimed count of its platform's output. Nature Reviews Drug Discovery summarized the approval as siRNA prophylaxis for hemophilia, in its April 2, 2025 coverage. What the approval did not establish is any general claim about the modality: each RNA drug stands on its own trial data in its own population.
How do regulators weigh RNA drugs differently?
The review logic mirrors other biologics with two modality-specific emphases. First, the pharmacology is upstream of the protein: an siRNA's effect size is anchored in measured target-protein reduction and its clinical correlate, not receptor occupancy. Second, the delivery chemistry defines the safety question — where the drug accumulates determines which organ systems reviewers watch. FDA's own announcement noted the dosing consideration that Qfitlia can be administered less frequently than existing options, per the agency's statement. Editors and readers should hold the same line regulators do: an approval names a drug, an indication, and a population, and extrapolation beyond that label is use outside the evidence.
What separates an RNA paper from an RNA drug?
The distance between a published sequence and an approved product is chemistry and measurement, in that order.
- Target validation in humans — demonstrating that reducing the target RNA moves the relevant protein and clinical marker in patients, not only in models.
- Delivery and durability — distribution to the intended tissue, dosing interval, and the trough-to-peak behavior that sets the schedule.
- Platform carryover — manufacturing and safety experience from prior conjugates of the same chemistry, which regulators weigh per filing.
Only after those three layers does a modality claim mean anything. The field's approved products now number in the dozens across siRNA, ASO, and mRNA classes, each review readable on its own terms — which is exactly how the next one will be read, too.
How does an RNA program read out differently in trials?
Endpoint logic follows the mechanism's time constant. Because target-protein knockdown is measurable early, RNA trials often pair a pharmacodynamic co-primary or early secondary — target reduction at a defined timepoint — with the clinical endpoint that justifies approval, so the readout separates delivery failure from target failure. Dosing intervals lengthen the design: a drug act for weeks per administration schedules its assessments around troughs, and trial statisticians account for the uneven exposure window between doses. Placebo-controlled blinding carries its own mechanical burden when administration schedules differ, which is part of why run-in and lead-in phases appear in this class more often than in small-molecule programs.
The review consequences are concrete. Labels for RNA drugs state the monitoring tied to the delivery organ and the dose-interval rules in the studied population, and trial publications report the knockdown curve alongside the clinical scale. For a professional reader, the knockdown curve is the more transferable fact: it tells whether the chemistry worked, whatever the clinical endpoint showed.
What limits the modality outside the liver?
Delivery, still. GalNAc conjugation reliably routes siRNA to hepatocytes, which is why liver-directed targets dominate the approved list; extrahepatic tissues lack a conjugate with the same record, and lipid nanoparticles favor liver and spleen by distribution. Sequence chemistry has partly answered stability and immune activation, but tissue selectivity remains the binding constraint on indication expansion. Durability is the second limit and the scheduling advantage: a long-acting exposure cannot be switched off quickly, and that asymmetry shapes both trial design and labeling for the class.
Timeline discipline completes the picture: sequence chemistry and conjugate selection precede IND-enabling toxicology, first-in-human pharmacodynamics often read out within weeks of dosing, and the class's trials tend to publish knockdown curves as a standing expectation. A reader who tracks the curve tracks the program's real trajectory.
Read that curve first, always, and the class becomes legible: mechanism, delivery, and schedule in one plot.
This article explains drug mechanisms and regulation for professional readers. It is not medical advice and does not address any individual's treatment.
